Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Relmada Therapeutics Inc (RLMD) PT Raised to $90 at Truist Securities
July 27, 2021 10:14 AM EDTTruist Securities analyst Joon Lee raised the price target on Relmada Therapeutics Inc (NASDAQ: RLMD) to $90.00 (from $75.00) while maintaining a Buy rating.
... MoreRelmada Therapeutics (RLMD) to Resume Trading at 8:30 a.m.
July 27, 2021 8:26 AM EDTRelmada Therapeutics (NASDAQ: RLMD) to Resume Trading at 8:30 a.m.
Relmada Therapeutics (RLMD) Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
July 27, 2021 7:35 AM EDTRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3... More
Relmada Therapeutics (RLMD) Halted, News Pending
July 27, 2021 7:25 AM EDTRelmada Therapeutics (NASDAQ: RLMD) Halted, News Pending
